18. The preparation according to claim 9 or 12, which is in the form of a film, troche, solution, suspension, freeze-dried preparation, chewing gum or spray.

19. Use of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in the manufacture of a medicament for preventing and/or treating a bipolar disorder, wherein said (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide is to be administered oral-mucosally to a human.

20. The use according to claim 19, wherein the oral-mucosal administration is sublingual administration or buccal administration.

21. The use according to claim 19, wherein (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide is to be administered in 0.05 - 1.0 mg per day.

22. The use according to claim 19, wherein the bipolar disorder is bipolar disorder I.

23. The use according to claim 19, wherein the bipolar disorder is a depression symptom associated with the bipolar disorder or maintenance of a remission phase of the bipolar disorder.

24. A drug for the prophylaxis and/or treatment of a bipolar disorder, which comprises, as an active ingredient, (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide to be oral-mucosally administered to a human.

25. The drug according to claim 24, wherein the oral-mucosal administration is sublingual administration or buccal administration.

18. The preparation according to claim 9 or 12, which is in the form of a film, troche, solution, suspension, freeze-dried preparation, chewing gum or spray.

19. A method for the prophylaxis and/or treatment of a bipolar disorder comprising administering (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide oral-mucosally to a human.

20. The method according to claim 19, wherein the oral-mucosal administration is sublingual administration or buccal administration.

21. The method according to claim 19, wherein (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide is administered in 0.05 - 1.0 mg per day.

22. The method according to claim 19, wherein the bipolar disorder is bipolar disorder I.

23. The method according to claim 19, wherein the prophylaxis and/or treatment of a bipolar disorder is a treatment of a depression symptom associated with the bipolar disorder or maintenance of a remission phase of the bipolar disorder.

24. A drug for the prophylaxis and/or treatment of a bipolar disorder, which comprises, as an active ingredient, (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide to be oral-mucosally administered to a human.

25. The drug according to claim 24, wherein the oral-mucosal administration is sublingual administration or buccal administration.